N-([(4-chlorophenyl)amino]carbonyl)-5,6,7,8-tetrahydro-2-naphthalenesulfonamide | 112894-43-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 四氢化萘
• 英文名称: N-([(4-chlorophenyl)amino]carbonyl)-5,6,7,8-tetrahydro-2-naphthalenesulfonamide
• 英文别名: 1-(4-chlorophenyl)-3-(5,6,7,8-tetrahydronaphthalen-2-ylsulfonyl)urea
• CAS: 112894-43-6
• 化学式: C₁₇H₁₇ClN₂O₃S
• 分子量: 364.853
• InChiKey: NEUZUPGMBJPKKC-UHFFFAOYSA-N

物化性质

• 熔点：
  163-165 °C
• 密度：
  1.404±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  83.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5,6,7,8-tetrahydro-naphthalene-2-sulfonic acid amide 、 对氯苯异氰酸酯 生成 N-([(4-chlorophenyl)amino]carbonyl)-5,6,7,8-tetrahydro-2-naphthalenesulfonamide
  参考文献：
  名称：

  Anti-tumor method and compounds

  摘要：

  这项发明提供了某些磺酰胺衍生物、它们的制药配方以及它们在哺乳动物易感性肿瘤治疗中的应用。

  公开号：

  US05594028A1

文献信息

• Sulfonyl ureas with anti-tumour activity
  申请人：ELI LILLY AND COMPANY

  公开号：EP0222475A1

  公开（公告）日：1987-05-20

  This invention provides sulfonamide derivatives useful in the treatment of susceptible neoplasms in warm-blooded animals of formula (I): in which A is -O-, -CH2-, -CH2CH2-, or -CH2O-; D is -CH2- or -O-; R, is hydrogen or halo, and R2 is halo or trifluoromethyl. E.g., N-([(4-chlorophenyl)amino]carbonyl)-2,3-dihydro-1H-indene-5-sulfonamide, m.p. 169-172°C, is prepared by reacting 2,3-dihydro-5-indenylsulfonamide with 4-chlorophenylisocyanate.

  本发明提供了可用于治疗温血动物易感肿瘤的磺酰胺衍生物，其式为(I)：其中A为-O-、-CH2-、-CH2CH2-或-CH2O-；D为-CH2-或-O-；R为氢或卤代，R2为卤代或三氟甲基。 例如，N-([(4-氯苯基)氨基]羰基)-2,3-二氢-1H-茚-5-磺酰胺，m.p.169-172℃，是由2,3-二氢-5-茚基磺酰胺与4-氯苯基异氰酸酯反应制备的。
• Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships
  作者：J. Jeffry Howbert、C. Sue Grossman、Thomas A. Crowell、Brent J. Rieder、Richard W. Harper、Kenneth E. Kramer、Eddie V. Tao、James Aikins、Gerald A. Poore

  DOI：10.1021/jm00171a013

  日期：1990.9

  A series of diarylsulfonylureas with exceptionally broad-spectrum activity against syngeneic rodent solid tumors in vivo is described. Their discovery resulted from a program dedicated to in vivo screening for novel oncolytics in solid tumor models, rather than traditional ascites leukemia models. The structures, oral efficacy, side-effect profile, and mechanism of action of these sulfonylureas appear to be distinct from previously known classes of oncolytics. An extensive series of analogues was prepared to probe structure-activity relationships (SAR), with particular focus on the substituent patterns of each aryl domain. Quantitative analysis of these substituent SARs, using the method of cluster significance analysis, showed the lipophilicity of the substituents to be the dominant determinant of activity. One compound from the series, LY186641 (104, sulofenur), has progressed to Phase I clinical trials as an antitumor drug.
• HOWBERT, J. JEFFRY;GROSSMAN, C. SUE;CROWELL, THOMAS A.;RIEDER, BRENT J.;H+, J. MED. CHEM., 33,(1990) N, C. 2393-2407
  作者：HOWBERT, J. JEFFRY、GROSSMAN, C. SUE、CROWELL, THOMAS A.、RIEDER, BRENT J.、H+

  DOI：——

  日期：——
• US5116874A
  申请人：——

  公开号：US5116874A

  公开（公告）日：1992-05-26
• US5594028A
  申请人：——

  公开号：US5594028A

  公开（公告）日：1997-01-14